Kala Pharmaceutic…
USUSDKala Pharmaceuticals Inc (US:KALA) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- kalarx.com
- Investoru Attiecības
- kalarx.com/investors/
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā Mītne
- Waltham, United States
- Izpilddirektors
- Avi Minkowitz
- Darbinieki
- 6
- Dibināts
- 2009
- Apgrozībā Esošās Akcijas
- 19.34 milj. uz 2026-08-14
- Brīvā Apgrozība
- 19.34 milj.
- Tirgus Kapitalizācija
- 5.68 milj. USD
- Iekšējās Personas
- 1.24%
- Institucionālie Investori
- 4.07%
- Nozare (SIC)
- Pharmaceutical Preparations
- P/E
- zaudējumi
- FCF
- —
- Parāds
- 26.9 milj. USD
- Peļņa un FCF — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
- NAV
Apraksts
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| Vanguard Capital Managem… | 1.14% | 220 623 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.14% | 220 623 | 2026-06-30 |
| Geode Capital Management… | 0.75% | 145 152 | 2026-06-30 |
| IWICKI MARK T. (Director… | ≈0.54% | 103 540 | 2025-10-23 |
| Vanguard Fiduciary Trust… | 0.52% | 101 396 | 2026-06-30 |
| Fidelity Concord Street… | 0.5% | 96 492 | 2026-07-31 |
| State Street Corporation | 0.46% | 88 570 | 2026-06-30 |
| Blackrock Inc. | 0.37% | 71 542 | 2026-06-30 |
| Northern Trust Corporati… | 0.22% | 41 606 | 2026-06-30 |
| KHARABI DARIUS (Officer) | ≈0.22% | 41 760 | 2025-10-22 |
| BRAZZELL ROMULUS KIM (Of… | ≈0.19% | 35 952 | 2025-10-22 |
| BAZEMORE TODD M (Directo… | ≈0.19% | 35 933 | 2025-10-22 |
| REUMUTH MARY (Chief Fina… | ≈0.15% | 28 906 | 2025-10-23 |
| Fidelity Concord Street… | 0.1% | 19 197 | 2026-07-31 |
| Fidelity Concord Street… | 0.09% | 17 397 | 2026-07-31 |
| KOVEN ANDREW IAN (Direct… | ≈0.09% | 16 972 | 2025-06-13 |
| ROSEN HOWARD B (Director… | ≈0.09% | 16 502 | 2025-06-13 |
| Fidelity Concord Street… | 0.07% | 12 832 | 2026-07-31 |
| PERRY GREGORY D (Directo… | ≈0.07% | 13 344 | 2025-06-13 |
| Qube Research & Technolo… | 0.06% | 11 073 | 2026-06-30 |
| Goldman Sachs Group Inc | 0.06% | 10 921 | 2026-06-30 |
| MYERS CHARLES DANIEL (Di… | ≈0.05% | 10 374 | 2025-06-13 |
| UBS Group AG | 0.05% | 9 057 | 2026-06-30 |
| Tower Research Capital L… | 0% | 616 | 2026-06-30 |
| John Hancock Variable In… | 0% | 355 | 2026-06-30 |
| BAKER BROS ADVISORS, L.P… | — | — | 2025-10-01 |
Pieslēdzies ar Google